Q4 2014 13F Holders as of 31 Dec 2014
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Total 13F shares
-
12,215,655
-
Share change
-
+131,355
-
Total reported value
-
$215,606,755
-
Price per share
-
$17.65
-
Number of holders
-
47
-
Value change
-
+$2,355,713
-
Number of buys
-
20
-
Number of sells
-
21
Institutional Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q4 2014
As of 31 Dec 2014,
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) was held by
47 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
12,215,655 shares.
The largest 10 holders included
FMR LLC, Redmile Group, LLC, BlackRock Advisors LLC, ADAGE CAPITAL PARTNERS GP LLC, Visium Asset Management, LP, FRANKLIN RESOURCES INC, BlackRock Fund Advisors, VANGUARD GROUP INC, WALL STREET ASSOCIATES, and Sarissa Capital Management LP.
This page lists
47
institutional shareholders reporting positions in this security
for the Q4 2014 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.